Rallybio Corp

NASDAQ RLYB

Data sourced from

and

Download Data

Rallybio Corp Cash Flow Coverage Ratio 2 year CAGR for the quarter ending December 31, 2023: -89.30%

Rallybio Corp Cash Flow Coverage Ratio 2 year CAGR is -89.30% for the quarter ending December 31, 2023. The cash flow coverage ratio evaluates a company's ability to cover its interest expense with its operating cash flow after deducting capital expenditures. It is calculated by dividing the difference between operating cash flow and capital expenditures by interest expense. This ratio indicates the company's ability to generate enough cash flow to service its interest payments. A higher ratio signifies better coverage and financial stability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Rallybio Corp Cash Flow Coverage Ratio for the quarter ending March 31, 2023 was 11.77, a 108.29% change year over year.
Rallybio Corp Cash Flow Coverage Ratio for the quarter ending March 31, 2022 was -141.93, a 88.16% change year over year.
Rallybio Corp Cash Flow Coverage Ratio for the quarter ending March 31, 2021 was -1,199.10, a -159.69% change year over year.
Rallybio Corp Cash Flow Coverage Ratio for the quarter ending March 31, 2020 was -461.75.

NASDAQ: RLYB

Rallybio Corp

CEO	Dr. Martin W. MacKay Ph.D.
IPO Date	July 29, 2021
Location	United States
Headquarters	234 Church Street, New Haven, CT, United States, 06510
Employees	30
Sector	Healthcare
Industry	Biotechnology

Description

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Key trends